382) Peripheral artery disease (PAD) produces significant disability attributable to lower extremity ischemia. |
PMID:23713861 DOI:10.3109/0284186X.2013.795286 |
2015 Current vascular pharmacology |
* Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease. |
- Peripheral artery disease (PAD) produces significant disability attributable to lower extremity ischemia. Limited treatment modalities exist to ameliorate clinical symptoms in patients with PAD. Growing evidence links microRNAs to key processes that govern disease expression in PAD including angiogenesis, endothelial function, inflammation, vascular regeneration, vascular smooth muscle cell function, restenosis, and mitochondrial function. MicroRNAs have been identified in circulation and may serve as novel biomarkers in PAD. This article reviews the potential contribution of microRNA to key pathways of disease development in PAD that may lead to microRNA-based diagnostic and therapeutic approaches. |
(1)100 *null* | (17)4 (PD) | (33)3 to | (49)2 condition, |
(2)39 and | (18)4 activity | (34)2 (CHD) | (50)2 development |
(3)16 is | (19)4 outcome | (35)2 (COPD) | (51)2 interval |
(4)13 in | (20)4 severity, | (36)2 (CVD), | (52)2 many |
(5)12 of | (21)4 the | (37)2 (GERD) | (53)2 multi-sectoral |
(6)9 (FMD) | (22)4 who | (38)2 (LSD) | (54)2 on |
(7)8 risk | (23)3 (CAD) | (39)2 (SC) | (55)2 onset |
(8)7 severity | (24)3 compared | (40)2 Control | (56)2 onset, |
(9)6 progression | (25)3 control | (41)2 activity, | (57)2 outbreaks |
(10)6 that | (26)3 course | (42)2 are | (58)2 patterns |
(11)6 was | (27)3 free | (43)2 as | (59)2 phobia |
(12)5 (CVD) | (28)3 has | (44)2 associated | (60)2 prevention |
(13)5 or | (29)3 management | (45)2 burden | (61)2 processes |
(14)5 state | (30)3 may | (46)2 by | (62)2 progression, |
(15)4 (AD) | (31)3 patients | (47)2 can | (63)2 surveillance |
(16)4 (HD) | (32)3 states | (48)2 characterized | (64)2 usually |
add keyword